^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Gastrointestinal Stromal Tumor
    Drug:Stivarga (regorafenib) (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    European Medicines Agency
    Published date:
    08/26/2013
    Excerpt:
    Stivarga is indicated as monotherapy for the treatment of adult patients with...unresectable or metastatic gastrointestinal stromal tumors (GIST) who progressed on or are intolerant to prior treatment with imatinib and sunitinib…
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    09/27/2012
    Excerpt:
    STIVARGA is a kinase inhibitor indicated for the treatment of patients with:...Locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Gastrointestinal Stromal Tumors: Systemic Therapy agents and regimens for unresectable GIST with significant morbidity…Preferred Regimen…Regorafenib (category 1)
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Gastrointestinal Stromal Tumors: Systemic Therapy agents and regimens for unresectable GIST with significant morbidity...Useful in certain circumstances…Everolimus + TKI…TKIs to be considered for use in combination with everolimus include imatinib, sunitinib, or regorafenib
    Secondary therapy:
    everolimus